Hydroxocobalamin Approach to Reduction of Calprotectin With Butyrate for Ulcerative Colitis Research
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a 4-week pilot, multicenter, randomized, double-blinded placebo controlled trial of
hydroxocobalamin and butyrate in ulcerative colitis (UC) that will occur in two phases. The
main objectives of this study are to determine the capacity of hydroxocobalamin and butyrate
to reduce calprotectin in those with inflammatory disease in UC to determine the safety and
preferential dose of hydroxocobalamin with butyrate in UC.